ARTICLE | Clinical News
Lyxumia lixisenatide regulatory update
November 19, 2012 8:00 AM UTC
EMA's CHMP issued a positive opinion recommending approval of an MAA for Lyxumia lixisenatide from Sanofi to treat Type II diabetes. The company plans to submit a regulatory application in the U.S. fo...